Recently, the State Drug Administration approved the marketing of injectable fizetumab declared by Tianjing Biopharmaceutical Co., Ltd. This variety, in combination with lenalidomide and dexamethasone, is used in adult patients with multiple myeloma who have received at least first-line treatment in the past. The marketing of this variety provides new treatment options for relevant patients.

Recently, the State Drug Administration approved the marketing of injectable fizetumab declared by Tianjing Biopharmaceutical Co., Ltd. This variety, in combination with lenalidomide and dexamethasone, is used in adult patients with multiple myeloma who have received at least first-line treatment in the past. The marketing of this variety provides new treatment options for relevant patients.